FEMY (Femasys) Beta: -6.6803 (As of Jun. 25, 2026)


FEMY Femasys Inc FEMY
55 GF Score
Price $3.60
GF Value $12.23
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Femasys Beta?

Femasys FEMY -1.91% 55 Beta is -6.6803 as of Jun. 25, 2026. GuruFocus rates FEMY with a GF Score™ of 55/100 and a GF Value™ of $12.23 (Possible Value Trap). The stock has 7 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Femasys's Beta is -6.6803.


Femasys  (NAS:FEMY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Femasys Beta Related Terms


Femasys Beta Historical Data

* Premium members only.

The historical data trend for Femasys's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Femasys Beta Chart

Femasys Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 -3.08 -7.92

Femasys Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.05 -3.94 -6.11 -7.92 -6.46

FEMY vs RVP, HBIO, ZJYL: Beta Comparison

For the Medical Instruments & Supplies subindustry, Femasys's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Femasys Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Femasys's Beta distribution charts can be found below:

* The bar in red indicates where Femasys's Beta falls into.


FEMY
55GF Score
Femasys Inc FEMY
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Femasys Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -6.6803 mean?
Femasys (FEMY) has a Beta of -6.6803 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Femasys and its competitors.
Is Femasys' Beta too high?
Femasys' current Beta is -6.6803. Overall, Femasys has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' Beta compare to RVP and HBIO?
Femasys' Beta of -6.6803 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Femasys and its competitors. Femasys's current Beta is -6.6803. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.23, compared to a current price of $3.60 — trading 70.6% below its estimated fair value. The current Beta is -6.6803. Femasys' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Femasys (FEMY), the current Beta is -6.6803 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Femasys (FEMY) Overvalued in 2026?

Based on GuruFocus' analysis, Femasys stock appears to be undervalued. The current stock price of $3.60 is trading 70.6% below its estimated GF Value™ of $12.23. GuruFocus considers Femasys to be Possible Value Trap.

Key valuation signals for FEMY:

  • Beta: -6.6803
  • GF Value™: $12.23 vs. price of $3.60 (70.6% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Femasys Business Description

Address 3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
55GF Score

Get the complete analysis for FEMY

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.60
Price
$12.23
GF Value